CDT Equity (NASDAQ:CDT) Posts Earnings Results

CDT Equity (NASDAQ:CDT) issued its earnings results on Wednesday. The company reported ($5.56) earnings per share (EPS) for the quarter, FiscalAI reports.

CDT Equity Trading Up 1.1%

CDT stock opened at $0.35 on Friday. The firm has a 50-day moving average of $0.92 and a two-hundred day moving average of $12.33. CDT Equity has a 12 month low of $0.30 and a 12 month high of $461.54. The company has a market cap of $1.73 million, a price-to-earnings ratio of -0.00 and a beta of 1.49.

CDT Equity shares are set to reverse split before the market opens on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 19th.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CDT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen cut CDT Equity to a “strong sell” rating in a report on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.